<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31618791</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>06</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1472-8206</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>6</Issue><PubDate><Year>2019</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Fundamental &amp; clinical pharmacology</Title><ISOAbbreviation>Fundam Clin Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Is TNF inhibitor exposure a risk factor for amyotrophic lateral sclerosis?</ArticleTitle><Pagination><StartPage>687</StartPage><EndPage>688</EndPage><MedlinePgn>687-688</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/fcp.12513</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bougea</LastName><ForeName>Anastasia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1st Department of Neurology, School of Medicine, Eginition Hospital, National and Kapodistrian University of Athens, Vassilisis Sophias Avenue 72-74, 11528, Athens, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Fundam Clin Pharmacol</MedlineTA><NlmUniqueID>8710411</NlmUniqueID><ISSNLinking>0767-3981</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000079424">Tumor Necrosis Factor Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000079424" MajorTopicYN="N">Tumor Necrosis Factor Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31618791</ArticleId><ArticleId IdType="doi">10.1111/fcp.12513</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Malaviya A.N., Mehra N.K. A fascinating story of the discovery &amp; development of biologicals for use in clinical medicine. Indian J. Med. Res. (2018) 148 263-278.</Citation></Reference><Reference><Citation>Zrubka Z., Gul&#xe1;csi L., Brodszky V. et al. Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis. Expert. Rev. Pharmacoecon. Outcomes Res. (2019) 1 1-13.</Citation></Reference><Reference><Citation>Li P., Zheng Y., Chen X. Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics. Front Pharmacol. (2017) 12 460.</Citation></Reference><Reference><Citation>Kaltsonoudis E., Zikou A.K., Voulgari P.V. et al. Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study. Arthritis Res. Ther. (2014) 16 R125.</Citation></Reference><Reference><Citation>Petitpain N., Devos D., Bagheri H. et al. Is TNF inhibitor exposure a risk factor for amyotrophic lateral sclerosis? Fundam. Clin. Pharmacol. (2019) 33 689-694. https://doi.org/10.1111/fcp.12480</Citation></Reference><Reference><Citation>Mehta P., Kaye W., Raymond J. et al. Prevalence of Amyotrophic Lateral Sclerosis - United States, 2015. MMWR Morb Mortal Wkly Rep. (2018) 67 1285-1289.</Citation></Reference><Reference><Citation>Chen X., Oppenheim J.J. Therapy: Paradoxical effects of targeting TNF signalling in the treatment of autoimmunity. Nat. Rev. Rheumatol. (2016) 12 625-626.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>